Cargando…
The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer
BACKGROUND: Evidence of the clinical impact of programmed death-ligand 1 (PD-L1) expression in small cell lung cancer (SCLC) is scarce and conflicting, even though atezolizumab became the first PD-L1 inhibitor approved by the US Food and Drug Administration (FDA) in recent years for the initial trea...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264325/ https://www.ncbi.nlm.nih.gov/pubmed/34295660 http://dx.doi.org/10.21037/tlcr-21-165 |